CKD Bio Valuation

Is A063160 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A063160 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate A063160's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate A063160's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A063160?

Key metric: As A063160 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for A063160. This is calculated by dividing A063160's market cap by their current revenue.
What is A063160's PS Ratio?
PS Ratio	0.8x
Sales	₩159.93b
Market Cap	₩122.34b

A063160 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	1.7x
Enterprise Value/EBITDA	-36.4x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does A063160's PS Ratio compare to its peers?

The above table shows the PS ratio for A063160 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	0.8x
A002620 Jeil Pharma Holdings	0.2x	n/a	₩131.4b
A002720 Kukje Pharma	0.8x	n/a	₩112.4b
A003120 Ilsung Is	1.5x	n/a	₩111.4b
A006620 DongKoo Bio & Pharma	0.6x	n/a	₩139.0b
A063160 CKD Bio	0.8x	n/a	₩122.3b

Price-To-Sales vs Peers: A063160 is expensive based on its Price-To-Sales Ratio (0.8x) compared to the peer average (0.8x).

Price to Sales Ratio vs Industry

How does A063160's PS Ratio compare vs other companies in the KR Pharmaceuticals Industry?

3 Companies	Price / Sales	Estimated Growth	Market Cap
A009290 Kwang Dong Pharmaceutical	0.1x	n/a	US$161.67m
A002620 Jeil Pharma Holdings	0.2x	n/a	US$94.48m
A000230 Ildong Holdings	0.1x	n/a	US$56.43m

No more companies available in this PS range

3 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: A063160 is good value based on its Price-To-Sales Ratio (0.8x) compared to the KR Pharmaceuticals industry average (0.8x).

Price to Sales Ratio vs Fair Ratio

What is A063160's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A063160 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	0.8x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate A063160's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

J2KBIO

₩54.5b

A bio venture company, provides active ingredients for cosmetics, functional food, and household products from natural materials and microbial fermentation.

A420570

₩9,830.00

6.0%

n/a

Hugel

₩3.0t

Develops and manufactures biopharmaceuticals in South Korea and internationally.

A145020

₩268,000.00

-3.4%

75.9%

Dong-A ST

₩544.1b

Develops, manufactures, and markets pharmaceutical products in South Korea and internationally.

A170900

₩62,300.00

-2.0%

8.6%